All In Biotech

Drug Trial Radar · NCT07171606

A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer(NSCLC) Patients

Last checked: Nov 20, 2026Latest source record: Dec 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

240

Planned (sponsor's estimate)

Start

Oct 24, 2025

Primary completion

Aug 31, 2026

Study completion Aug 31, 2027

Sponsor

Sponsor type
Industry
First posted
Sep 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study includes two parts, part 1 is SSGJ-706 monotherapy therapy for advanced NSCLC and part 2 is SSGJ-706 combination therapy for advanced NSCLC

Conditions

  • First-line Advanced NSCLC Patients

Interventions

  • SSGJ-706Drug

    PD-1/PD-L1 bispecific antibody

  • pemetrexed /carboplatinDrug

    chemotherapy

  • Carboplatin/PaclitaxelDrug

    chemotherapy

  • PD-1 Inhibitor + ChemotherapyDrug

    control group

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR)Time frame: 12 months
  2. Incidence and severity of Adverse EventsTime frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Institute of The Shanghai Pulmonary Hospital

    Shanghai, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.